|
|
6. New Analogue Advances
in Glycaemic Control - Introducing
NovoRapid®Sunday,
September 17, 2000
09:00-12:30
| 09:00-09:10
|
Introduction
Lois Jovanovic, USA |
| Part
I: Building
the Future |
| 09:10-09:30 |
Novo Nordisk Commitment to
Analogue Insulins
P. Kurtzhals, Denmark |
| 09:30-09:50
|
Will Analogues Further Improve
Metabolic Control?
TBA |
| 10:00-10:20 |
Moving Towards Physiological
Insulinemia - the NovoRapid® Concept
Stephen Colagiuri, Australia |
| 10:30-11:00 |
Coffee Break |
| Part
II: NovoRapid® - New Advances in
Clinical Use |
| 11:00-11:15
|
Improved Care and Quality of
Life
TBA |
| 11:20-11:50
|
NovoRapid® - a Reliable Choice
for Intensive Therapy
Stephanie Amiel, UK |
| 12:00-12:30
|
Sustaining Improved Glycaemic
Control
Robert E. Ratner, USA |
| 12:30-13:00
|
Discussion and Round-Up |
GENERAL, REGISTRATION AND
ABSTRACT ENQUIRIES
PROGRAMME
 FOR
Crowne Plaza Hotel, Jerusalem
Lois Jovanovic, USA
Novo Nordisk A/S
FOR
GENERAL, REGISTRATION AND ABSTRACT ENQUIRIES
LOGISTICS
Peter Roervig
Novo Nordisk A/S
Novo Alle, DK-2880 Bagsvaerd, DENMARK
Tel: +45 44 42 1666
Fax: +45 44 42 1390
E-mail: pwr@novo.dk
SCIENTIFIC
Danilo Verge
Novo Nordisk A/S
Novo Alle, DK-2880 Bagsvaerd, DENMARK
Tel: +45 44 42 8367
Fax: +45 44 42 2120
E-mail: dver@novo.dk
|
